The ED$_{50}$ and ED$_{95}$ of oxytocin infusion rate for maintaining uterine tone during elective caesarean delivery: a dose-finding study

Xiao Wei Qian, Dan M. Drzymalski, Chang Cheng Lv, Fei He Guo, Lu Yang Wang and Xin Zhong Chen*

Abstract

Background: The 90% effective dose (ED$_{90}$) of oxytocin infusion has been previously estimated to be 16.2 IU h$^{-1}$. However, bolus administration of oxytocin prior to the infusion may decrease the infusion dose required. The aim of this study was to estimate the ED$_{95}$ for oxytocin infusion after a bolus at elective caesarean delivery (CD) in nonlaboring parturients.

Methods: We performed a randomized, triple blinded study in 150 healthy term parturients scheduled for elective CD under epidural anaesthesia. After delivery of the infant and i.v. administration of 1 IU oxytocin as a bolus, Participants were randomized to receive oxytocin infusion at a rate of 0, 1, 2, 3, 5, or 8 IU h$^{-1}$, to be given for a total of 1 h. Uterine tone assessed by the blinded obstetrician as either adequate or inadequate. Secondary outcomes included estimated blood loss (EBL), requirement for supplemental uterotonic agents, and development of side effects.

Results: The 95% effective dose (ED$_{95}$) of oxytocin infusion was estimated to be 7.72 IU h$^{-1}$ (95% confidence interval 5.80–12.67 IU h$^{-1}$). With increasing oxytocin infusion rate, the proportion of parturients who needed rescue oxytocin bolus or secondary uterotonic agents decreased. No significant among-group differences in the EBL and oxytocin-related side effects were observed.

Conclusions: In parturients who receive a 1 IU bolus of oxytocin during elective cesarean delivery, an infusion rate of oxytocin at 7.72 IU h$^{-1}$ will produce adequate uterine tone in 95% of paruritents. These results suggest that the total dose of oxytocin administered in the postpartum period can be decreased when administered as an infusion after oxytocin bolus.

Keywords: Caesarean section, Oxytocin, Postpartum haemorrhage prevention

Background

Although oxytocin has been administered for postpartum haemorrhage prophylaxis for several decades [1], there still remains considerable variability in the approach to its administration during caesarean delivery (CD). As an example, a slow i.v. bolus dose of up to 5 IU has been advocated by several authors [2, 3], but Carvalho et al. estimated the minimum effective dose (ED) of oxytocin bolus to result in adequate tone in 90% of parturients (ED$_{90}$) during elective CD in nonlaboring parturients to be 0.35 IU [4]. These results suggest that doses lower than those commonly used would not only be effective, but would also decrease the risks of side effects [4–8].

When administered as an infusion, Lavoie et al. estimated the ED$_{90}$ of oxytocin during elective CD in nonlaboring women to be 16.2 IU h$^{-1}$ [5]. While this approach is effective, it exposes patients to significant amounts of oxytocin in the postpartum period. Part of the reason that the ED$_{90}$ is so high with this approach is...
because the infusion needs to be administered for some duration of time prior to achieving therapeutic plasma levels.

By administering an oxytocin bolus prior to initiation of infusion, therapeutic plasma concentrations are rapidly achieved and are simply maintained by the infusion [5]. Therefore, the aim of this study was to estimate the ED$_{95}$ (the minimum effective dose (ED) of oxytocin bolus to result in adequate tone in 95% of parturients) for oxytocin infusion after a bolus at elective CD in non-bolus to result in adequate tone in 95% of parturients). Our hypothesis was that the ED$_{95}$ of the infusion would be lower than in previous studies that did not administer a bolus prior to the infusion.

**Methods**

The Ethical Committee of the Women’s Hospital, Zhejiang University School of Medicine (Hangzhou, China) approved this study on April 5, 2018 (No. 20180010). This study was registered on the Chinese Clinical Trial Register (ChiCTR1800015532).

The study was performed at the Women’s Hospital, Zhejiang University School of Medicine from April 9 to July 31, 2018. After providing written informed consent, 150 healthy term parturients scheduled for elective CD were enrolled in this prospective, randomized, triple-blinded, placebo-controlled, dose-finding study. The present study adhered to CONSORT guideline.

Inclusion criteria were American Society of Anaesthesiologists Physical Status II, age 18–40 years old, body mass index $< 40$ kg/m$^2$, singleton pregnancy, ≥37 weeks’ gestation age, elective CD planned with a Pfannenstiel incision, and planning epidural anaesthesia. Parturients were only recruited if the individual performing the CD was 1 of 5 experienced obstetricians who agreed to have their patients participate in this study. Exclusion criteria included maternal refusal, emergency CD, active labor, ruptured membranes, pregnancy-induced hypertension, placental abnormalities (including placenta previa), multiple gestation, uterine fibroids, history of prior peripartum hemorrhage, coagulation disorders, oxytocin allergy, contraindication to epidural anaesthesia, and the need for pharmacological anxiolysis.

Prior to initiation of this study, sealed, opaque envelopes were prepared using the Microsoft Excel RAND function to determine study subject allocation. Participants were randomized to oxytocin infusion at a rate of 0, 1, 2, 3, 5, or 8 IU h$^{-1}$, to be given for a total of 1 h. On the day of surgery, an anaesthetist not involved in the study prepared an oxytocin infusion according to the randomization assignment. After filling a syringe with the total number of units of oxytocin that were to be administered during the hour-long infusion (e.g. if the patient was randomized to receive 8 IU h$^{-1}$, a total of 8 IU were drawn into the syringe), the syringe was filled with normal saline to make a total volume of 50 ml. This syringe was then given to the anaesthetist of record with instructions to administer the infusion at 50 ml over 1 h. By having all study subjects receive the same infusion rate (50 ml h$^{-1}$) but with a different total dose of oxytocin, the study subject, obstetrician, and anaesthetist responsible for the care of the patient were all blinded to the actual dose of oxytocin.

Upon entry into the operation room, an 18-gauge i.v. catheter was placed in the study subject’s lower forearm and 500 ml lactated Ringer’s solution was administered. With the parturient in the left lateral decubitus position, an epidural catheter was placed at the L$_{1-2}$ interspace by an anaesthetist not involved in the study. Lidocaine 2% with epinephrine 1:200,000 was administered in 5 ml increments to a total of 15–20 ml until a T6 sensory level to pinprick was obtained.

Upon initiation of epidural anaesthesia, non-invasive blood pressure (NIBP) and maternal heart rate (HR) were measured at 3-min intervals. An i.v. bolus of ephedrine 5 mg was administrated when hypotension was accompanied by bradycardia (HR $< 50$ beats min$^{-1}$), and an i.v. bolus of phenylephrine 100 μg was administrated when hypotension occurred without bradycardia. Hypotension was defined as a decrease in systolic blood pressure greater than 20% from baseline, which had been previously estimated upon admission by the averaging of three consecutive measurements.

Surgery commenced with onset of adequate surgical anaesthesia. After clamping of the umbilical cord and delivery of the infant, all parturients were given an i.v. bolus of oxytocin 1 IU over 15 s as previously recommended [6], after which the oxytocin infusion previously prepared according to the randomization scheme was initiated at 50 ml h$^{-1}$.

After initiation of the oxytocin infusion, uterine tone (UT) was assessed by the obstetrician as adequate or inadequate every 3 min until the peritoneum was closed based on previously described methods [5–7]. If UT was assessed as inadequate, an i.v. bolus of oxytocin 1 U was administered. If UT was still judged to be inadequate after two such oxytocin boluses, then secondary uterotonic agents (i.m. carboprost tromethamine 0.25 mg or i.v. carbetocin 0.1 mg) were administered upon the obstetrician’s request. The oxytocin infusion was continued until discharge from the post anaesthetic care unit (PACU). If another syringe was needed in PACU, the same dose of oxytocin as the original was prepared.

The primary study outcome was adequacy of UT during the CD. Secondary outcomes included estimated blood loss (EBL), hemoglobin (Hb) and haematocrit (HCT) levels (at time of PACU discharge and on postoperative day 1), proportion of participants requiring administration of supplemental oxytocin boluses or alternative uterotonic
agents, and side effects (hypotension, bradycardia, tachycardia [defined as HR ≥120 beats min⁻¹], nausea, vomiting, flushing, chest pain, or dyspnea). Postpartum hemorrhage (PPH), defined as EBL > 1000 ml [6], and the need for perioperative blood transfusion were also noted. EBL was estimated using the following formula [4, 9]: EBL (mL) = [(preoperative HCT - postoperative HCT)/preoperative HCT] × (weight in kilograms) × 85.

Statistical analysis
Data are expressed as mean ± SD, median (inter-quartile range), or n (%) where appropriate. Data were assessed for normal distribution of variance using the Kolmogorov-Smirnov test. Normally distributed data were assessed by one-way analysis of variance. Nonnormally distributed data were assessed by the Kruskal-Wallis test. Categorical variables were assessed using the Chi-square test or Fisher exact test where appropriate. The Chi-square trend test (linear-by-linear association) was used to analyze the frequency of administration of additional uterotonic agents in the six groups. Statistical analyses were performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.

The dose-response relation for oxytocin infusion was determined using probit regression [10, 11]. An effective oxytocin infusion rate (success) was defined as a rate that provided adequate UT throughout the CD, from initiation of the oxytocin infusion to closure of the peritoneum, in the absence of administration of additional uterotonic agents. Data for successful responses for each infusion rate were used to plot a sigmoid dose-response curve. The ED50 and ED95 of an effective oxytocin infusion rate were then determined.

Sample size calculation
The sample size was estimated using the Cochran-Armitage Test for the trend in proportions using PASS® (Version 11.0.7, NCSS, LLC, Kaysville, UT). Based on pilot data in which the proportion of parturients with adequate UT was 0.5, 0.5, 0.7, 0.8, 0.85, and 0.9 in those receiving oxytocin infusions at a rate of 0, 1, 2, 3, 5, or 8 IU h⁻¹, respectively, a total sample of 78 subjects (13 per group) were required to achieve 90% power to detect a linear trend using a two-sided Z test with continuity correction and a significance level of 0.05. We planned to recruit 150 subjects to account for potential attrition.

Results
Of a total 150 parturients who were enrolled, 145 completed the study (Fig. 1). There were no significant baseline differences among the six groups in demographic characteristics or preoperative Hb and HCT values (Table 1).

The adequacy of UT during CD in the setting of each of the 6 randomized groups is summarized in Fig. 2. Using probit analysis, the dose-response curve was plotted (Fig. 3) from which we estimated the ED50 to be 0.05 IU h⁻¹ (95% confidence interval [CI] -2.51 to 1.25 IU h⁻¹) and the ED95 to be 7.72 IU h⁻¹ (95% CI 5.80 to 12.67 IU h⁻¹).

The results of the secondary outcomes are summarized in Table 2. The proportion of study subjects who required administration of supplemental oxytocin boluses or alternative uterotonic agents decreased with increasing oxytocin infusion rates. Compared with the placebo infusion group, fewer patients in the 3, 5, and 8 IU h⁻¹ oxytocin groups needed rescue oxytocin bolus

Assessed for eligibility and randomized
(n = 150)

Oxytocin 0 IU h⁻¹
(n = 25)

Oxytocin 1 IU h⁻¹
(n = 25)

Oxytocin 2 IU h⁻¹
(n = 25)

Oxytocin 3 IU h⁻¹
(n = 25)

Oxytocin 5 IU h⁻¹
(n = 25)

Oxytocin 8 IU h⁻¹
(n = 25)

Excluded none

2 patients excluded
Uterine Rupture were found during surgery n=1
Withdrawn by surgeon n=1

1 patient excluded
Alternative uterotonic requested by surgeon n=1

2 patients excluded
Unanticipated placental partial implantation n=1
Alternative uterotonic requested by surgeon n=1

Analysed (n = 25)

Analysed (n = 23)

Analysed (n = 24)

Analysed (n = 23)

Analysed (n = 25)

Analysed (n = 25)

Fig. 1 Study flow diagram. IU, units
(52% vs 17, 12, and 8%; \( P = 0.012, 0.002, \) and 0.001, respectively) or secondary uterotonic agents (24% vs 0, 0, and 0%; \( P = 0.023, 0.022, \) and 0.022, respectively). No significant differences in EBL and total i.v. crystalloid volume infused were observed. Hb and HCT levels measured at the time of PACU discharge and on postoperative day 1 were similar among the groups. There were no cases of PPH, postoperative Hb < 7 g dL\(^{-1}\), or postoperative HCT < 24% observed. No parturients received blood transfusion perioperatively.

Side effects are shown in Table 3. We found no significant differences in the incidence of hypotension, tachycardia, nausea, flushing, and chest pain. Tachycardia was observed in one parturient who received the 8 IU h\(^{-1}\) oxytocin infusion. No parturients experienced bradycardia, vomiting, or dyspnea during the study period.

### Discussion

The primary finding of this dose-response study was that, in nonlaboring women undergoing elective CD, the ED\(_{50}\) of an oxytocin infusion was 0.05 IU h\(^{-1}\) (95% CI – 2.51 to 1.25 IU h\(^{-1}\)) and the ED\(_{95}\) was 7.72 IU h\(^{-1}\) (95% CI 5.80 to 12.67 IU h\(^{-1}\)). In addition, fewer parturients in 3, 5, and 8 IU h\(^{-1}\) oxytocin infusion groups required rescue oxytocin bolus or secondary uterotonic agents compared with placebo. Finally, no significant differences in the EBL or the incidence of oxytocin-related side effects were observed among groups.

The ED\(_{90}\) of oxytocin as an infusion (without a pre-infusion bolus) during elective CD has been previously estimated to be between 16.2 IU h\(^{-1}\) and 17.4 IU h\(^{-1}\) [12]. We found that when a pre-infusion bolus is administered, the ED\(_{95}\) of an oxytocin infusion is reduced to 7.72 IU h\(^{-1}\). The finding that the ED\(_{95}\) of an oxytocin infusion in the setting of a pre-infusion bolus is lower than without is clinically significant because it suggests that lower doses overall may be needed when administered in this fashion. By administering lower doses, the risk for side effects would presumably also be decreased, thus improving the care of this patient population.

The finding that the ED\(_{95}\) of an oxytocin infusion in the setting of a pre-infusion bolus is lower than without...
is not entirely surprising. The basic principles of pharmacokinetics dictate that bolus administration of oxytocin results in rapid attainment of therapeutic plasma concentrations [5]. Therefore, the purpose of the infusion in this setting is simply to maintain those levels after the initial bolus. On the other hand, when an infusion is started without a bolus, there will be a delay until therapeutic plasma concentrations are attained, which may increase the risk for uterine atony.

Our study is consistent with prior study which emphasize that a bolus of oxytocin alone is insufficient [9]. When compared to the placebo group (no oxytocin infusion), those who received an infusion of 3, 5, and 8 IU h\(^{-1}\) required fewer rescue oxytocin boluses or secondary uterotonic agents. This finding is not surprising because oxytocin has an extremely short half-life (4–10 min) [9], so in order to maintain UT after the initial bolus, an infusion would be absolutely necessary.

While our study findings have important clinical implications, there are several limitations that should be considered. First, given that assessment of adequate UT was done subjectively, it is unknown if similar results might be obtained if a different set of obstetricians made the assessment. However, given that Lavoie et al. [5] and George et al. [12] obtained similar results using similar methods, it is likely that our results would be similar even if UT were to be assessed by different providers. Second, because we studied only nonlaboring parturients undergoing elective CD, it is likely that the ED\(_{95}\) would be different if studying in a different population. Finally, while we chose to administer a bolus of 1 IU because it is well above the ED\(_{90}\) oxytocin [4], a smaller or larger

![Fig. 3 The ED\(_{50}\) and ED\(_{95}\) of oxytocin infusion. Regression plot of the probit value vs. the infusion rate of oxytocin. The 0.5 and 0.95 y-intercepts indicate the ED\(_{50}\) and ED\(_{95}\), respectively.](image-url)

| Table 2 Secondary outcomes | 0 IU h\(^{-1}\) | 1 IU h\(^{-1}\) | 2 IU h\(^{-1}\) | 3 IU h\(^{-1}\) | 5 IU h\(^{-1}\) | 8 IU h\(^{-1}\) | P value |
|-----------------------------|----------------|----------------|----------------|----------------|----------------|----------------|---------|
| Estimated blood loss (ml)   | 693 ± 426      | 701 ± 394      | 619 ± 322      | 631 ± 404      | 625 ± 472      | 658 ± 330      | 0.977   |
| Intravenous crystalloid (ml)| 900 ± 210      | 993 ± 283      | 992 ± 273      | 1004 ± 296     | 1024 ± 255     | 984 ± 206      | 0.622   |
| Hb in PACU (g dL\(^{-1}\))  | 10.7 ± 1.0     | 10.8 ± 1.3     | 10.5 ± 0.9     | 10.9 ± 1.1     | 10.8 ± 1.2     | 10.7 ± 0.9     | 0.864   |
| HCT in PACU (%)             | 32.4 ± 2.8     | 32.2 ± 3.8     | 31.7 ± 2.9     | 32.5 ± 3.1     | 31.9 ± 3.4     | 32.1 ± 2.5     | 0.956   |
| Hb on postoperative day 1 (g dL\(^{-1}\)) | 11.5 ± 1.1 | 11.3 ± 1.5 | 11.3 ± 1.1 | 11.8 ± 1.3 | 11.1 ± 1.1 | 11.6 ± 1.0 | 0.354 |
| HCT on postoperative day 1 (%) | 34.0 ± 3.0 | 33.3 ± 4.3 | 33.5 ± 3.0 | 34.7 ± 3.5 | 32.6 ± 2.9 | 34.2 ± 2.7 | 0.303 |
| Rescue oxytocin required [n (%)] | 13 (52) | 12 (52) | 7 (29) | 4 (17) | 3 (12) | 2 (8) | 0.000 |
| Secondary uterotonic agents required [n (%)] | 6 (24) | 1 (4) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 0.000 |

Data are expressed as mean ± SD or n (%). Compared with 0 IU h\(^{-1}\) oxytocin infusion group, fewer patients in the 3, 5, and 8 IU h\(^{-1}\) oxytocin groups needed rescue oxytocin bolus (52% vs 17, 12, and 8%; \(P = 0.012, 0.002,\) and \(0.001\), respectively) or secondary uterotonic agents (24% vs 0, 0, and 0%; \(P = 0.023, 0.022,\) and \(0.022\), respectively). PACU postanesthetic care unit, Hb hemoglobin, HCT hematocrit
bolus could have altered the ED$_{95}$. Further studies should be performed to determine if a similarly low ED$_{95}$ of oxytocin infusion is found if a lower bolus dose of oxytocin is used.

Conclusions
This study demonstrates that the ED$_{95}$ of oxytocin infusion is decreased when a small bolus of oxytocin is administered prior to the infusion. This finding is important because excessive oxytocin administration is associated with side effects, including nausea, vomiting, and hypotension. Future studies should be performed to better understand if a smaller dose of the bolus could be used and still result in an overall decreased need for oxytocin infusion.

Abbreviations
CD: Caesarean delivery; EBL: Estimated blood loss; ED: Effective dose; Hb: Haemoglobin; HCT: Haematocrit; HR: Heart rate; NIBP: Non-invasive blood pressure; PACU: Post anaesthetic care unit; PPH: Postpartum haemorrhage; UT: Uterine tone

Acknowledgements
We would like to thank all obstetric staffs for their help.

Authors’ contributions
XQ helped in designing the study and writing the first draft of the manuscript; CL helped in recruiting and data collection; XC helped in designing the study and writing the manuscript; All authors read and approved the final manuscript.

Funding
This research was supported by the Zhejiang Provincial Natural Science Foundation of China under grant NOLY13H150007; and the National Natural Science Foundation of China under grant NO. 81501702. The funding help in the data collection, data analysis and the manuscript writing.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate
The Ethical Committee of the Women’s Hospital, Zhejiang University School of Medicine (Hangzhou, China) approved the study on April 5, 2018. The reference number is No. 20180010. The written informed consent from all parturients participated in the present study were obtained.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1'Department of Anesthesia, Women’s Hospital, Zhejiang University School of Medicine, Xueshi Road 1, Hangzhou 310006, China. 2Department of Anesthesiology and Perioperative Medicine, Tufts Medical Center, Boston, MA, USA.

Received: 6 March 2019 Accepted: 19 December 2019

Published online: 31 December 2019

Table 3 Oxytocin-related adverse effects

| Effect                  | 0 U h$^{-1}$ | 1 U h$^{-1}$ | 2 U h$^{-1}$ | 3 U h$^{-1}$ | 5 U h$^{-1}$ | 8 U h$^{-1}$ | P value |
|-------------------------|--------------|--------------|--------------|--------------|--------------|--------------|---------|
| Hypotension             | 5 (20)       | 4 (17)       | 4 (17)       | 4 (17)       | 3 (12)       | 2 (8)        | 0.879   |
| Tachycardia             | 0            | 0            | 0            | 0            | 0            | 1 (4)        | 1.000   |
| Nausea                  | 5 (20)       | 3 (13)       | 2 (8)        | 1 (4)        | 2 (8)        | 3 (13)       | 0.604   |
| Flushing                | 5 (20)       | 6 (26)       | 5 (21)       | 6 (26)       | 5 (20)       | 5 (20)       | 0.986   |
| Chest pain              | 4 (16)       | 2 (9)        | 1 (4)        | 1 (4)        | 1 (4)        | 2 (8)        | 0.582   |

Data are expressed as n (%)

References
1. West R, West S, Simons R, McGlennan A. Impact of dose-finding studies on administration of oxytocin during caesarean section in the UK. Anaesthesia. 2013;68:1021–5.
2. Wedisinghe L, Macleod M, Murphy DJ. Use of oxytocin to prevent haemorrhage at caesarean section—a survey of practice in the United Kingdom. Eur J Obstet Gynecol Reprod Biol. 2008;137:27–30.
3. King KL, Douglas MJ, Unger W, Wong A, King RA. Five unit bolus oxytocin at cesarean delivery in women at risk of atony: a randomized, double-blind, controlled trial. Anesth Analg. 2010;111:1460–6.
4. Carvalho JC, Balli M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol. 2004;104:1005–10.
5. Lavoie A, McCarthy RL, Wong CA. The ED90 of prophylactic oxytocin infusion after delivery of the placenta during caesarean delivery in laboring compared with nonlaboring women: an up-down sequential allocation dose-response study. Anesth Analg. 2015;121:59–64.
6. Duffield A, McKenzie C, Carvalho B, Ramachandran B, Yin V, El-Sayed YY, Riley ET, Butwick AJ. Effect of a high-rate versus a low-rate oxytocin infusion for maintaining uterine contractility during elective cesarean delivery: a prospective randomized clinical trial. Anesth Analg. 2017;124:857–62.
7. Butwick AJ, Coleman L, Cohen SE, Riley ET, Carvalho B. Minimum effective bolus dose of oxytocin during elective cesarean delivery. Br J Anaesth. 2010;104:338–43.
8. Sartain JB, Barry JJ, Howat PW, McCormack DI, Bryant M. Intravenous oxytocin bolus of 2 units is superior to 5 units during elective caesarean section. Br J Anaesth. 2008;101:822–6.
9. Sheehan SR, Montgomery AA, Carey M, et al. ECSSIT Study Group. Oxytocin bolus versus intravenous oxytocin and infusion for control of blood loss at elective caesarean section: double blind, placebo controlled, randomised trial. BMJ. 2011;343:d4661.
10. Carvalho B, Dunbin M, Drover DR, Cohen SE, Ginosar Y, Riley ET. The ED50 and ED95 of intrathecal isobaric bupivacaine with opioids for cesarean delivery. Anesthesiology. 2005;103:605–12.
11. Khaw KS, Ngan Kee WD, Wong EL, Liu JY, Chung R. Spinal ropivacaine for cesarean section: a dose-finding study. Anesthesiology. 2001;95:1346–50.
12. George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED (90) of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing cesarean delivery. Can J Anaesth. 2010;57:578–82.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.